SCHEMBL14511634

SCHEMBL14511634

Cc1nc(C(=O)N2CCOCC2)c(C(C)(C)C)[nH]1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.45
▸ PIN1 Q13526 2/20 0.42
▸ HTT P42858 3/20 0.40
▸ POLB P06746 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ HSP90AB1 P08238 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HTR2C P28335 2/20 0.39
▸ ATM Q13315 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ SPR P35270 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14511647 0.87 ALDH1A1 (0.44) ALDH1A1PIN1HTTUSP2MAPT
SCHEMBL14511631 0.76 ALDH1A1 (0.41) ALDH1A1PIN1HTTPOLBUSP2
SCHEMBL14511629 0.74 MAPT (0.43) ALDH1A1PIN1HTTMAPTPKM
SCHEMBL14511635 0.71 RAB9A (0.50) ALDH1A1PIN1HTTSMN1; SMN2LMNA
SCHEMBL14511637 0.70 PIN1 (0.50) ALDH1A1PIN1HTTPOLBMAPT
SCHEMBL14511632 0.69 MEN1 (0.44) ALDH1A1PIN1POLBMAPTSMN1; SMN2
SCHEMBL8264513 0.65 FGFR1 (0.55) ALDH1A1HTTHSP90AA1HSP90AB1MAPT
SCHEMBL14803631 0.65 HSP90AA1 (0.51) ALDH1A1PIN1HSP90AA1HSP90AB1MAPT
SCHEMBL12335793 0.64 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2GAASPR
SCHEMBL14736498 0.64 PDE10A (0.51) ALDH1A1PIN1HTTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070105900-A1 Pharmaceutical compounds ATEX THERAPEUTICS, LIMITED (GB) 2007-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105900-A1 Pharmaceutical compounds AURKA, AURKC, CDK1 ALDH1A1 1875/4885PIN1 705/4885HTT 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback